1. | StockCats12 | |
2. | ItsNewman | |
3. | levawill000 | |
4. | 7998mom | |
5. | wenday47 |
1. | StockCats12 | |
2. | ItsNewman | |
3. | levawill000 | |
4. | 7998mom | |
5. | wenday47 |
1. | spottedgecko7 06/13/2018 Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses |
2. | levawill000 02/08/2018 WOW! check out this PT |
3. | StockCats12 04/03/2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
4. | StockCats12 12/01/2017 5 Biotech and Pharma Stocks with FDA Catalysts this December |
5. | ItsNewman 01/08/2018 Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts |
6. | 7998mom 03/20/2018 Announces a publication in the Journal of Experimental Medicine |
7. | levawill000 03/10/2018 $ACRS in the news |
8. | levawill000 04/06/2018 Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada |
9. | ItsNewman 03/21/2018 Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine |